Abstract
Chorea-acanthocytosis and McLeod syndrome are neurodegenerative disorders caused by mutations in VPS13A and XK, respectively. While clinically similar, the molecular link between these two proteins remained unclear. This study demonstrates that VPS13A, an ER-anchored lipid transfer protein, localizes to ER-plasma membrane (PM) contacts by binding the scramblase XK. This interaction is mediated by the VPS13A PH domain and is competitive with its binding to other organelles. These findings suggest a model where bulk lipid transfer is coupled with membrane scrambling, providing a unified mechanism for the pathogenesis of these diseases.
The Problem: A Shared Clinical Fate
The human body relies on precise lipid distribution across cellular membranes. Two rare but devastating neurodegenerative diseases—Chorea-acanthocytosis (ChAc) and McLeod syndrome (MLS)—result from mutations in the proteins VPS13A and XK, respectively. Despite having different genetic causes, the diseases are clinically indistinguishable, characterized by the death of neurons in the brain's movement centers (the caudate nucleus) and misshapen red blood cells.
Scientists knew these proteins were functional partners, but the "where" and "how" remained elusive. VPS13A was known to act as a bridge, moving lipids from the ER to mitochondria or lipid droplets. However, XK resides at the plasma membrane. This paper addresses the missing link: how does an ER-anchored protein (VPS13A) interact with a PM-resident protein (XK), and what does this partnership actually do?
Structural Insights and Dual Localization
Using AlphaFold2, the researchers modeled VPS13A as a massive 22nm rod with a hydrophobic groove designed for bulk lipid transport. This structure acts like a "bridge" or "slide," allowing lipids to flow between membranes without entering the watery cytoplasm.
The study revealed that VPS13A's C-terminal Pleckstrin Homology (PH) domain acts as a specific "hook" that can bind either to mitochondria or to the second cytosolic loop (L2) of XK at the PM. This dual targeting suggests that the cell can "toggle" VPS13A between different organelles depending on physiological needs.
The VPS13A-XK Interaction Mechanism
The interaction is highly specific and regulated. The researchers discovered that XK possesses an internal "lock" mechanism where its L2 and L3 loops interact, hiding the VPS13A binding site. When this interaction is disrupted—either by specific mutations or potentially by a yet-unknown physiological signal—XK "opens up," robustly recruiting VPS13A to the plasma membrane.
Chemically induced clustering of XK at the PM directly recruited VPS13A in real-time, confirming their physical association in live cells. This recruitment competes with VPS13A's localization to mitochondria, providing a mechanism for the protein to switch between different tethering functions.
Coupling Transfer to Scrambling
XK is a scramblase—it flips lipids between the inner and outer layers of a single membrane. The authors propose a model where VPS13A delivers lipids from the ER to the inner layer of the PM, and XK immediately "scrambles" them to the outer layer. This ensures the membrane expands or changes composition evenly, a process likely critical for the health of Medium Spiny Neurons (MSNs) in the human caudate nucleus, where both proteins are highly expressed.
Future Directions
While the study identifies the molecular bridge, the "key" that naturally unlocks XK remains unknown. Furthermore, proving that defective cell surface exposure of specific lipids, like Phosphatidylserine, directly causes neurodegeneration is a major next step in understanding and potentially treating ChAc and MLS.
Summary updated